基于国家药品抽检的骨刺片质量分析

doi:10.19803/j.1672-8629.20210776

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (3): 292-295.
DOI: 10.19803/j.1672-8629.20210776

基于国家药品抽检的骨刺片质量分析

刘静, 刘燕, 郑笑为^#, 汪祺, 何风艳, 王菲菲, 王亚丹, 何轶, 聂黎行, 胡晓茹, 戴忠, 马双成^*

中国食品药品检定研究院,北京 100050

收稿日期:2021-08-21 出版日期:2023-03-15 发布日期:2023-03-17
通讯作者: ^* 马双成,男,研究员·博导,中药民族药物质基础与质量安全评价。E-mail：masc@nifdc.org.cn;^#为共同通信作者。
作者简介:刘静,女,博士,中药标准物质与中药质量控制。
基金资助:
国家科技重大专项重大新药创制（2018ZX09735-006）

Quality analysis of Guci tablets based on national drug evaluation sampling

LIU Jing, LIU Yan, ZHENG Xiaowei^#, WANG Qi, HE Fengyan, WANG Feifei, WANG Yadan, HE Yi, NIE Lixing, HU Xiaoru, DAI Zhong, MA Shuangcheng^*

National Institutes for Food and Drug Control, Beijing 100050, China

Received:2021-08-21 Online:2023-03-15 Published:2023-03-17

摘要/Abstract

摘要： 目的通过骨刺片国家药品抽检,对全国骨刺片质量状况进行综合考察与分析。方法通过开展标准检验与探索性研究工作,特别是根据标准检验过程中发现的问题,同时结合处方中含 4 味毒性药材以及大处方的主要特点,重点围绕药品安全性与有效性等方面进行深入研究,对骨刺片的质量现状进行深入而全面地分析。结果骨刺片标准检验合格率为98. 1%,不合格样品 2 批次,为士的宁含量测定项不符合规定。探索性研究发现部分批次样品存在砷、汞超标,存在一定安全性风险;部分批次样品可能存在原料药材投料质量差或未按处方投料的问题。结论上述研究发现的安全性与有效性相关问题应予以关注与重视。建议生产企业进一步加强源头控制,同时应加强投料生产过程控制,严把质量关,从而更好地保障药品安全性与有效性。

关键词: 骨刺片, 国家药品评价抽检, 乌头碱, 士的宁, 马钱子碱, 重金属, 黄曲霉素, 质量分析

Abstract: Objective To evaluate the quality of Guci tablets based on national drug evaluation sampling. Methods This quality analysis was based on inspections of standards and research. Since the prescription involved four toxic crude drugs, in-depth research on safety and effectiveness was carried out by targeting the problems found during inspections of standards. Results The qualified rate of inspections of standards was 98.1%. There were 2 batches of unqualified samples and their contents of strychnine fell short of the standard. Research indicated that arsenic and mercury exceeded standard limits in some samples. High concentrations of arsenic and mercury posed a risk to safety. In addition, some crude drugs might have been of poor quality or crude drugs were not used according to the prescriptions. Conclusion Importance should be attached to the safety and effectiveness of drugs. It is recommended that manufacturers strengthen the control over the source of drugs and production processes in order to ensure the safety and effectiveness of medicines.

Key words: Guci tablets, national drug evaluation sampling, aconitine, strychnine, brucine, heavy metal, aflatoxin, quality analysis

中图分类号:

R917

刘静, 刘燕, 郑笑为, 汪祺, 何风艳, 王菲菲, 王亚丹, 何轶, 聂黎行, 胡晓茹, 戴忠, 马双成. 基于国家药品抽检的骨刺片质量分析[J]. 中国药物警戒, 2023, 20(3): 292-295.

LIU Jing, LIU Yan, ZHENG Xiaowei, WANG Qi, HE Fengyan, WANG Feifei, WANG Yadan, HE Yi, NIE Lixing, HU Xiaoru, DAI Zhong, MA Shuangcheng. Quality analysis of Guci tablets based on national drug evaluation sampling[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 292-295.

参考文献

[1] Drug Standard of Ministry of Public Health. Traditional Chinese Medicine Preparations Volume 17 WS₃-B-3290-98《中药成方制剂》[S]. 1998: 202.
[2] ZHANG S, YUAN XF, ZHANG Y.Determination of naringin and paeoniflorin in Gu Ci Tablet by HPLC[J].Guangzhou Chemical Industry(广州化工), 2015, 43(16): 140-142.
[3] CAO L, FENG YL, WANG YC, et al.Study on quality control of Guci Tablets[J].Drug Standards of China(中国药品标准), 2011, 12(3): 191-195.
[4] YUAN XF, ZHANG S.Research on HPLC fingerprint of Guci Tablets[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2015, 35(4): 314-317.
[5] ZHANG YM, XIE QF, LU J, et al.Revision study on quality standard of Radix Aconiti Kusnezoffii[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2010, 30(5): 940-944.
[6] LIU S, LIU XY, LI Y, et al.Experimental study on acute toxicity of the Aconiti kusnezoffii Radix and its processed products[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(9): 513-521.
[7] LI ZY, ZHANG SF, CHANG HS, et al.Changes of DDAs content affected by different processing time and its relationship with safety of processed Fuzi[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2009, 34(9): 1086-1089.
[8] ZHENG Q, LU HW, HAO WW, et al.Study on hydrolysis of Aconitum alkaloids and quantitative analysis method of their hydrolysates[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2011, 46(9): 652-656.
[9] HE FY, HE Y, DAI Z, et al.Simultaneous determination of 7 alkaloids in Guci tablets by HPLC-MS/MS[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2018, 38(10): 1810-1816.
[10] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People's Republic of China,Volume I I(中华人民共和国药典二部)[M]. Beijing: China Medical Science Press. 2020: 201.
[11] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People's Republic of China,Volume I I(中华人民共和国药典二部)[M]. Beijing: China Medical Science Press.2020: 41-42.
[12] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People's Republic of China,Volume I I(中华人民共和国药典二部)[M]. Beijing: China Medical Science Press. 2020:248.
[13] SONG HB, DU XX.Literature study on adverse reactions of Strychni semen and analysis of risk factors[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(7): 411-416.
[14] PAN JH, YAN GJ, ZHOU JJ.Determination of strychnine and brucine in Semen Strychni Pulveratum by HPLC assay[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2010, 45(13): 1024-1029.
[15] WANG FF, ZHANG YM, ZHENG XW, et al.Study on assay method of brucine and strychnine in Guci Tablets[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2018, 38(10): 1824-1829.
[16] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People's Republic of China,Volume I I(中华人民共和国药典二部)[M]. Beijing: China Medical Science Press.2020: 53.
[17] LIU J, ZHANG JP, MENG J, et al.Acute toxic effect of Guci Tablets on zebrafish embryo development[J]. Drug Evaluation Research(药物评价研究), 2018, 41(10): 1804-1809.
[18] ZHA YF, NIE LX, YU JD, et al.Study on identification methods of Guci Tablets by high pergormance thin layer chromatography[J]. China Pharmaceuticals(中国药业), 2018, 27(8): 18-21.
[19] WANG YD,DAI Z,SUN CL,et al.Quality control of Guci tablets using UPLC-ELSDfingerprint analysis coupled with chemometrics[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2018, 43(6):1156-1161.
[20] WANG YD, DAI Z, HE FY, et al.Simultaneous determination of 14 ompounds in Guci tablets using RPLC-MS/MS method[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2019, 39(4): 595-607.

基于国家药品抽检的骨刺片质量分析

Quality analysis of Guci tablets based on national drug evaluation sampling

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

[1]	聂黎行, 陈佳, 张烨, 赵慧, 戴忠, 马双成. 板蓝根中外源性有害残留的全面检查及风险评估[J]. 中国药物警戒, 2023, 20(4): 379-382.
[2]	关皓月, 刘年, 藄梦洁, 孙百浩, 刘雪婧, 胡钖, 牛剑钊. 盐酸多奈哌齐片质量评价[J]. 中国药物警戒, 2023, 20(12): 1375-1381.
[3]	钟盈盈, 王赵, 左甜甜, 李耀磊, 李海亮, 马双成. 党参中外源性重金属及相关元素检测和风险评估研究进展[J]. 中国药物警戒, 2023, 20(11): 1309-1315.
[4]	李耀磊, 王赵, 李海亮, 昝珂, 金红宇, 马双成. 朱砂七药材中重金属残留和相关元素形态价态分析[J]. 中国药物警戒, 2023, 20(11): 1234-1237.
[5]	左甜甜, 王赵, 郭愿生, 魏锋, 金红宇, 马双成. 基于多元素快速筛查西洋参中毒性元素的非致癌性与致癌性风险评估[J]. 中国药物警戒, 2023, 20(10): 1108-1112.
[6]	李耀磊, 张晓朦, 张冰, 林志健, 昝珂, 金红宇, 马双成. 基于临床用药导向的中药有害成分风险评估方法应用研究[J]. 中国药物警戒, 2022, 19(5): 475-480.
[7]	冯群, 姚景春, 李欣, 荆凡波, 张娜, 张贵民. 川乌生物碱类成分致心脏毒性的网络分析与机制预测[J]. 中国药物警戒, 2022, 19(1): 62-68.
[8]	左甜甜, 金红宇, 王赵, 余坤子, 康帅, 逄瑜, 孙磊, 马双成. 地龙中重金属及有害元素的含量分析与安全性评价[J]. 中国药物警戒, 2021, 18(5): 450-453.
[9]	陈影（译）, 游云（校）*. 联合DNA鉴定及有毒物质、重金属检测加强对中药上市后监测[J]. 中国药物警戒, 2017, 14(9): 572-576.
[10]	刘斌, 翟伟, 马宁, 周立新. 医疗器械不良事件报告表质量评价方法探索[J]. 中国药物警戒, 2011, 8(3): 165-167.